The Hemodynamic Effects of SGLT2i in Acute Decompensated Heart Failure

• Status: Not yet recruiting
• Trial end date: 2023-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The main purpose of this study is to observe hemodynamic effects of initiating sodium-glucose co-transporter 2 inhibitors (SGLT2i) in patients admitted to the intensive care unit (ICU) with acute decompensated heart failure.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Chicago

Criteria

Inclusion Criteria:

1. Age > 18 years old

2. Heart Failure Reduced ejection fraction (HFrEF) of 40 or less

3. Estimated glomerular filtration rate (eGFR) > 30milliliters(ml)/minute(min)/1.73 meter(m)2

4. Admitted to CCU by advanced heart failure service for decompensated heart failure requiring continuous hemodynamic monitoring with a pulmonary artery catheter

Exclusion Criteria:

1. Diagnosis of type 1 diabetes mellitus

2. eGFR < 30ml/min/1.73m2

3. age < 18 years old

4. Jehovah's witnesses

5. Diagnosis of group 1 pulmonary arterial hypertension

6. Insulin requirement above standard low dose sliding scale

7. Patients with a history of diabetic ketoacidosis (DKA)

8. Allergies to SGLT2i medications

9. History of intolerance to SGLT2i medications

10. Patients listed for cardiac transplantation or on mechanical support

11. Pregnant or breastfeeding